

# Dolasetron

Printed from <https://www.cancerquest.org/patients/drug-reference/dolasetron> on 02/22/2025



Brand name: Anzemet®

IUPAC: (3R)-10-oxo-8-azatricyclo[5.3.1.0<sup>3,8</sup>]undec-5-yl 1H-indole-3-carboxylate

FDA approval: Yes

[Manufacturer Link](#)

Usage:

Dolasetron mesylate (Anzemet®) is used to prevent nausea and vomiting associated with cytotoxic effects of chemotherapy. Dolasetron is administered in pill form.<sup>1</sup> In December 2010, the U.S. FDA blocked the use of the injected (intravenous) form of the drug for the prevention of nausea due to chemotherapy.<sup>2</sup>

- <sup>1</sup>Anzemet.. Prescribing Information. Aventis Pharmaceuticals. September, 2016. [<http://www.anzemet.com>]
- <sup>2</sup><https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-use-anzemet-dolasetron-mesylate>

Mechanism:

Dolasetron works by blocking the reception of serotonin at 5-HT<sub>3</sub> receptors. When these receptors are bound by serotonin, they induce nausea and the vomiting reflex.

The structure below shows the 3D conformer Dolasetron.

Side effects:

The most common side effects associated with the use of Anzemet® during chemotherapy regimens are headache, fatigue and diarrhea. The intravenous version of the drug was associated with abnormal heart rhythms.